Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Nov 05, 2023 4:35pm
135 Views
Post# 35718513

RE:Cytodyn letter to shareholders-putting -surprising candor

RE:Cytodyn letter to shareholders-putting -surprising candor

While I dont expect THTX to copy cat this message a good way to start the healing process would be to describe what went wrong take full responsibilty .I think the initial bad call was the Convert more than 5 years ago and the inability to lessen the impact of having to re imburse the Convert other than hoping to win the lottery .... Instead we got shellshscked by the Marathon awfull deal which was the trigger of last week 'svery dilutive Financing ...
I also think that the Purchase of Katana i.e the lottery ticket without  having neither the cash nor the know how to properly carry this very risk endeavour is a center piece of the failed strategy

Paul and the whole BOD apparently were not able to see the warning signs  early enough ....if they knew then they did not take the necessary measures to avoid a 90% drop in the SP
Confidence needs to be restored... If that happens then we stand a chance to make money
Finally I hope as a starter that the guidance for the current fiscal year  revenue will be met with 3 weeks to go
 




 

<< Previous
Bullboard Posts
Next >>